Abbott Laboratories (NYSE:ABT) Price Target Raised to $134.00 at BTIG Research

Abbott Laboratories (NYSE:ABT) had its price target lifted by BTIG Research from $131.00 to $134.00 in a report published on Friday,Benzinga reports. BTIG Research currently has a buy rating on the healthcare product maker’s stock.

Several other analysts have also recently issued reports on ABT. The Goldman Sachs Group cut their price objective on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. Benchmark decreased their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Leerink Partners dropped their price objective on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research note on Tuesday, April 21st. Oppenheimer cut their target price on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Finally, Wells Fargo & Company decreased their price objective on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $118.61.

Abbott Laboratories Stock Performance

Shares of ABT opened at $100.71 on Friday. The company has a market capitalization of $175.41 billion, a price-to-earnings ratio of 32.59, a price-to-earnings-growth ratio of 1.70 and a beta of 0.61. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49. The stock has a 50 day moving average price of $89.89 and a 200 day moving average price of $102.17.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The firm had revenue of $12.51 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same quarter last year, the company posted $1.26 earnings per share. The business’s revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts predict that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is currently 70.59%.

Insider Activity

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was purchased at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the transaction, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. The trade was a 0.15% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The shares were purchased at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 0.46% of the company’s stock.

Institutional Investors Weigh In On Abbott Laboratories

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nia Impact Advisors LLC boosted its position in shares of Abbott Laboratories by 2.2% during the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after purchasing an additional 79 shares in the last quarter. American National Bank of Texas lifted its holdings in shares of Abbott Laboratories by 2.4% during the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock valued at $427,000 after purchasing an additional 79 shares in the last quarter. Park Place Capital Corp grew its position in shares of Abbott Laboratories by 11.0% in the 4th quarter. Park Place Capital Corp now owns 815 shares of the healthcare product maker’s stock valued at $102,000 after purchasing an additional 81 shares during the period. Clayton Financial Group LLC grew its position in shares of Abbott Laboratories by 1.4% in the 4th quarter. Clayton Financial Group LLC now owns 6,217 shares of the healthcare product maker’s stock valued at $779,000 after purchasing an additional 84 shares during the period. Finally, Jamison Private Wealth Management Inc. increased its position in shares of Abbott Laboratories by 0.5% during the fourth quarter. Jamison Private Wealth Management Inc. now owns 15,854 shares of the healthcare product maker’s stock worth $1,986,000 after acquiring an additional 85 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
• Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.